AcquisitionsApr 30, 2026, 07:37 AM
APTOF: Hanmi Acquisition Closing Delayed to May Due to Regulatory Approvals
AI Summary
Aptose Biosciences Inc. announced a delay in the closing of its previously announced acquisition by Hanmi Pharmaceutical Co. Ltd. and HS North America Ltd. The delay is attributed to pending Korean regulatory approvals, which are still in progress. The parties now anticipate completing the Arrangement in May and do not expect the review to prevent closing. Under the terms, Aptose shareholders will receive C$2.41 in cash per common share, representing a 28% premium over the 30-day VWAP.
Key Highlights
- Acquisition by Hanmi Pharmaceutical delayed due to pending Korean regulatory approvals.
- Target closing for the Arrangement is now the month of May.
- Aptose shareholders to receive C$2.41 in cash per common share.
- C$2.41 per share represents a 28% premium over Aptose's 30-day VWAP of C$1.88.